Department of Anesthesiology, Shenzhen Traditional Chinese Medicine Hospital, 4th Medical School of Guangzhou University of Traditional Chinese Medicine, Shenzhen, Guangdong 518033.
Department of Rehabilitation, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150006, P.R. China.
Mol Med Rep. 2023 Jan;27(1). doi: 10.3892/mmr.2022.12890. Epub 2022 Nov 4.
Stroke is one of the leading causes of death from diseases. When the blood supply to the brain tissue is interrupted, neuronal core death occurs due to the lack of glucose and oxygen in min. Blood pressure lowering after ischemic stroke was proven to be an effective strategy to achieve neurovascular protection and reduce the risk of recurrent stroke. Astragaloside IV is a pure small molecular compound isolated from , and it is well documented that astragaloside IV has neuroprotective effect on cerebral ischemia reperfusion (CIR) injury through many mechanisms, including antioxidant, anti‑inflammatory and anti‑apoptotic. The present study adopted mean arterial pressure (MAP) monitoring, neurological scoring, 2,3,5‑triphenyltetrazolium chloride staining, enzyme‑linked immuno‑sorbent assay, western blotting and other experimental methods to investigate the effect of astragaloside IV on systemic blood pressure during CIR in a middle cerebral artery occlusion animal model. It was demonstrated that astragaloside IV pretreatment significantly alleviated CIR injury as previously reported. In addition, the elevation of MAP during CIR was significantly inhibited by astragaloside IV administration. Moreover, it was revealed that the expression of Na+‑K+‑2Cl‑ cotransporter isoform 1 in the hypothalamus was inhibited and the subsequent synthesis of vasopressin was reduced by astragaloside IV pretreatment in the CIR animal model. In conclusion, astragaloside IV may alleviate CIR injury partially by lowering systemic blood pressure.
中风是疾病导致死亡的主要原因之一。当脑组织的血液供应中断时，由于分钟内缺乏葡萄糖和氧气，神经元核心会死亡。缺血性中风后的血压降低已被证明是实现神经血管保护和降低中风复发风险的有效策略。黄芪甲苷是从 中分离得到的一种纯小分子化合物，有大量文献证明黄芪甲苷通过多种机制对脑缺血再灌注（CIR）损伤具有神经保护作用，包括抗氧化、抗炎和抗细胞凋亡。本研究采用平均动脉压（MAP）监测、神经评分、2,3,5-三苯基氯化四氮唑染色、酶联免疫吸附试验、Western blot 等实验方法，探讨了黄芪甲苷对 CIR 动物模型中系统性血压的影响。结果表明，如先前报道的那样，黄芪甲苷预处理可显著减轻 CIR 损伤。此外，黄芪甲苷给药显著抑制了 CIR 期间的 MAP 升高。此外，研究还揭示了在 CIR 动物模型中，黄芪甲苷预处理可抑制下丘脑 Na+-K+-2Cl-共转运体亚型 1 的表达，从而减少血管加压素的合成。综上所述，黄芪甲苷可能通过降低系统性血压部分减轻 CIR 损伤。
